OPEN APP
Home >Companies >News >Aurobindo Pharma gets FDA nod to launch fenofibrate tablets in US
Aurobindo now has a total of 259 ANDA approvals, including 222 final and 37 tentative approvals from FDA. Photo: Bloomberg
Aurobindo now has a total of 259 ANDA approvals, including 222 final and 37 tentative approvals from FDA. Photo: Bloomberg

Aurobindo Pharma gets FDA nod to launch fenofibrate tablets in US

Fenofibrate is used to treat high levels of cholesterol and triglycerides in the blood

Hyderabad: Aurobindo Pharma Ltd on Friday said it has got final approval from the US Food and Drug Administration (FDA) to manufacture and market cholesterol-lowering fenofibrate tablets in 48 milligram (mg) and 145 mg dosage forms.

“This product is expected to be launched in Q1 FY16-17," Aurobindo said in a statement.

The approved abbreviated new drug application (ANDA) is the generic version of AbbVie Inc.’s Tricor® tablets.

Fenofibrate is used to treat high levels of cholesterol and triglycerides in the blood.

“The approved product has an estimated market size of $412 million for the 12 months ending March 2016," the company said, quoting US-based healthcare information provider IMS Health.

This is the 75th ANDA to be approved out of the Unit VII formulation facility in Hyderabad for manufacturing oral non-antibiotic products, the company said.

Aurobindo now has a total of 259 ANDA approvals, including 222 final and 37 tentative approvals from FDA.

Shares of Aurobindo dropped 0.41% and were trading at 801.90 at 1.15pm, while the benchmark Sensex index declined 0.25% to 25,207.54 points.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
Edit Profile
My Reads Redeem a Gift Card Logout